QIAGEN and ARTUS Announce Supply Agreement to Provide QIAamp Sample Preparation Kits for Use with Artus’ Diagnostic Products
Dec 10 2003

QIAGEN and ARTUS Announce Supply Agreement to Provide QIAamp Sample Preparation Kits for Use with Artus’ Diagnostic Products

Venlo, the Netherlands and Hamburg, Germany - December 10, 2003: QIAGEN GmbH, a wholly owned subsidiary of QIAGEN N.V. (Nasdaq: QGENF, Frankfurt, Prime Standard: QIA) and artus GmbH today announced that they have entered into a manufacturing and supply agreement. Pursuant to this agreement, artus will integrate QIAGEN's nucleic acid sample preparation products in its diagnostic systems for use in the detection of a variety of infectious diseases such as SARS, Herpes simplex virus -1/-2, EBV, West Nile Virus, Malaria, Salmonella. These diagnostic solutions employ artus' RealArt® amplification technology which is based on the polymerase chain reaction (PCR) technology to which artus holds a non-exclusive license from Roche.

The customized solutions will incorporate specific versions of QIAGEN's sample preparation modules and technologies, including QIAGEN's well established QIAamp technology and will be distributed by artus and its distributors in combination with the real-time PCR-based diagnostic solutions under the brand PureArt.

QIAGEN's proprietary nucleic acid sample preparation and handling technologies provide high reliability and efficiency in both, DNA and RNA separation and purification in molecular diagnostics. Following nucleic acid sample extraction, processed samples will be transferred onto artus' RealArt system for amplification and detection.

"We are very pleased that artus has selected QIAGEN nucleic acid purification kits as a front-end preparation solution to their real-time amplification and detection system," said Dr. Frank Krieg-Schneider, Director Strategic Alliances at QIAGEN. "Artus is a visionary and technology-leading molecular diagnostics company and its RealArt® solutions are considered some of the most sensitive and efficient diagnostic solutions. Efficient extraction and purification of target nucleic acids is key to the sensitivity and reliability of nucleic acid testing. Methods such as PCR possess significant and technological challenges in clinical settings. QIAGEN's technology and market leadership in nucleic acid purification in molecular diagnostics is adding substantial value to the development of standardized and highly efficient solutions in this emerging and rapidly growing market."

"We are very happy about the supply agreement we have signed with QIAGEN", said Dr. Ulrich Spengler, managing director, artus GmbH. "QIAGEN's expertise in nucleic acid extraction and purification reflected in their sample preparation modules and technologies addresses the requirements in reliability and efficiency of RNA and DNA preparation in molecular diagnostics and will add significant value to our RealArt PCR assays."

About QIAGEN

QIAGEN N.V., a Netherlands holding company with subsidiaries in Germany, the United States, Japan, the United Kingdom, Switzerland, France, Italy, Australia, Norway, Austria and Canada, believes it is the world's leading provider of innovative enabling technologies and products for the separation, purification and handling of nucleic acids. The Company has developed a comprehensive portfolio of more than 320 proprietary, consumable products for nucleic acid separation, purification and handling, nucleic acid amplification, as well as automated instrumentation, synthetic nucleic acid products and related services. QIAGEN's products are sold in more than 42 countries throughout the world to academic research markets and to leading pharmaceutical and biotechnology companies. In addition, the Company is positioning its products for sale into developing commercial markets, including DNA sequencing and genomics, nucleic acid-based molecular diagnostics, and genetic vaccination and gene therapy. QIAGEN employs approximately 1,600 people worldwide.

Further information on QIAGEN can be found at http://www.qiagen.com/.

About artus GmbH

artus GmbH is a biotechnology company based in Hamburg, Germany, with subsidiaries in Malaysia and the United States. Established as a spin-off of the Bernhard-Nocht-Institute for Tropical Medicine in 1998, artus has an experienced team of medical scientists, microbiologists and molecular biologists. artus is one of the first companies worldwide to offer a broad range of licensed real-time PCR kits for pathogen detection applying PCR in the field of infectious disease. Having been granted the license for commercial distribution of PCR in January 2002, artus is entitled to produce and sell diagnostic PCR kits for the diagnosis of herpes viruses, tropical infection diseases and relevant pathogens for veterinary medicine. artus develops and produces all PCR kits according to the highest quality standards and earlier this year released the first commercially available test kit for the detection of a new form of the coronavirus suspected of causing SARS, as well as the first CE-marked real-time PCR kit in Europe for detection of herpes simplex virus (HSV) in human diagnostics.

Additional information about artus and its products can be found on the company's web site at www.artus-biotech.com.

 

Certain of the statements contained in this news release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products and markets and operating results are forward-looking, such statements are based on current expectations that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations and risks of dependency on logistics), variability of operating results, the commercial development of the DNA sequencing, genomics and synthetic nucleic acid-related markets, nucleic acid-based molecular diagnostics market, and genetic vaccination and gene therapy markets, competition, rapid or unexpected changes in technologies, fluctuations in demand for QIAGEN's, products (including seasonal fluctuations), difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products, the ability of QIAGEN to identify and develop new products and to differentiate its products from competitors, and the integration of acquisitions of technologies and businesses. For further information, refer to the discussion in reports that QIAGEN has filed with the U.S. Securities and Exchange Commission (SEC).

Contacts:

Peer M. Schatz
Chief Financial Officer
QIAGEN N.V.
+49 2103 29 11702
e-mail: peer.schatz@QIAGEN.com

Dr. Solveigh Mähler
Manager Investor Relations
QIAGEN GmbH
+49 2103 29 11710
e-mail: solveigh.maehler@QIAGEN.com

Frank Krieg-Schneider
Director Strategic Alliances
QIAGEN GmbH
+49 2103 29 16266
e-mail: mailto:frank.krieg-schneider@QIAGEN.com

SOCIAL SHARING

Share this page